• Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
• Full data will be presented at the 2023 American Diabetes Association’s 83^rd Scientific Sessions
• Novel dual glucagon/GLP-1 receptor agonist BI 456906 is part of the collaboration between Boehringer Ingelheim and Zealand Pharma

“Obesity is one of many cardio-renal-metabolic diseases, which together represent one of the fastest growing health challenges worldwide. The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “With our longstanding heritage in cardio-renal-metabolic diseases, we are excited by the findings and potential implications for millions of people who urgently need healthcare solutions.”

“We are both enthusiastic about these data and encouraged by the clinical outcomes announced today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma we continue our long-term commitment to the discovery and development of novel differentiated peptide therapeutics that target critical metabolic pathways to achieve substantial weight loss while addressing the complex pathophysiology of overweight and obesity.”

In 2016, more than 1 billion people worldwide were living with cardio-renal-metabolic (CRM) diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure and cardiovascular disease^1-10. Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades¹¹. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society¹¹.